Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study-Reference-Cited by-同舟云学术

Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study

Published:2010 Issue:5 Volume:25 Page:287-293
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J. Clin. Apheresis

Author:

Muratov Vladislaw,Lundahl Joachim,Mandic-Havelka Aleksandra,Elvin Kerstin,Öst Åke,Shizume Yasumasa,Furuya Kaoru,Löfberg Robert

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jca.20255/fullpdf

Reference36 articles.

1. Suppression of interleukin-1beta- and tumour necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis;Andoh;J Gastroenterol,2004

2. Leukocytapheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis;Andoh;Ther Apher Dial,2005

3. Decreased numbers of FoxP3 positive and TLR-2 positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis;Muratov;J Gastroenterol,2008

4. Downregulation of interferon-g parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study;Muratov;Int J Colorectal Dis,2006

5. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column;Sawada;Curr Pharm Des,2003

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease;Transfusion and Apheresis Science;2017-10

2. Arginase activity in alternatively activated macrophages protects PI3Kp110δ deficient mice from dextran sodium sulfate induced intestinal inflammation;European Journal of Immunology;2014-09-25

3. Reduction in bradykinin generation during leukocytapheresis using novel cellsorbaTMCS-180S: Effects of changing the filling solution;Journal of Clinical Apheresis;2013-09-11

4. Kinetics of the soluble IL-1 receptor type I during treatment with an LCAP filter in patients with inflammatory bowel disease;Journal of Clinical Apheresis;2012

5. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis;Journal of Clinical Apheresis;2011-11-14